SIOX NASDAQ
Sio Gene Therapies Inc.
1W: +22.9%
1M: +22.9%
3M: +21.0%
1Y: +4.9%
3Y: -83.5%
5Y: -94.9%
$0.48
Last traded 2024-02-07 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.25-0.5
Volume7,588
Avg Volume58,098
Beta1.08
Dividend$0.43
Analyst Ratings
Company Info
CEODavid W. Nassif
Employees12
SectorHealthcare
IndustryBiotechnology
IPO Date2015-06-11
Websitesiogtx.com
130 West 42nd Street
New York City, NY 10036
US
New York City, NY 10036
US
877 746 4891
About Sio Gene Therapies Inc.
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Meswani Parag V | A-Award | 153,700 | — | 2022-02-08 |
| Nassif David W. | A-Award | 546,500 | — | 2022-02-08 |
| Meswani Parag V | 0 | — | 2022-01-28 | |
| Meswani Parag V | 8,033 | — | 2022-01-28 | |
| Meswani Parag V | 15,625 | $9.20 | 2022-01-28 |